Hadeel S. Hadi Ali A. Ghazzay


Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. Chronic hyperglycemia and high blood pressure are the main risk factors for the development of DN. 30%–40% of patients with diabetes develop DN, of which 5%–10% eventually progress to end-stage renal disease (ESRD). The present study was performed for the evaluation of Angiotensin II levels and their relationship with type 1 and type 2 diabetes mellitus and diabetic nephropathy in Al-Qadisiyah Province. To achieve this aim, 100 samples were collected, divided into 2 groups: those who are 40 Type 1 diabetes patients (20 T1DM with nephropathy and 20 T1DM without nephropathy); 40 Type II diabetes patients (20 T2DM with nephropathy and 20 T2DM without nephropathy); and healthy controls. Samples were collected from Al-Diwaniyah Teaching Hospital and Diabetes Center in Al-Qadisiyah Province from March 2022 to December 2022. Five milliliters of venous blood samples were obtained from each person under sterile conditions. Serum Ang-II (Angiotensin II) concentrations were estimated by an enzyme-linked immunosorbant assay. The data were analyzed using a variety of statistical methods. The results showed a significant (p < 0.05) decrease in serum Ang-II (Angiotensin II) in all patient groups, compared to diabetic subjects and healthy controls. Conclusions. Ang-II (Angiotensin II) is considered a very good diagnostic marker in type 1 diabetes and a good diagnostic marker in type 2 diabetes mellitus and diabetic nephropathy. This indicates that angiotensin II plays an important role in the development and progression of diabetic nephropathy.

Download Statistics



Diabetic nephropathy (DN), Diabetes Mellitus, Angiotensin II.

Citation Format